Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;22(7):e303-e313.
doi: 10.1016/S1470-2045(20)30666-5. Epub 2021 Apr 20.

Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer

Affiliations
Review

Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer

Maria Alice Franzoi et al. Lancet Oncol. 2021 Jul.

Abstract

The growing availability of more effective therapies has contributed to an increased survival of patients with breast cancer. In hormone receptor-positive early disease, increased survival is strongly correlated with the use of adjuvant endocrine therapy, but this therapy can cause side-effects that have major consequences in terms of treatment adherence and patients' quality of life. In premenopausal breast cancer survivors, these side-effects might be even more prominent due to the abrupt suppression of oestrogen associated with the most intense endocrine therapies. An important ambition of cancer care in the 21st century is to recover pre-cancer quality of life and emotional and social functions, which is only possible through the mitigation of the side-effects of anticancer treatments. This Review presents a comprehensive summary of the efficacy and safety data of the available interventions (hormonal and non-hormonal pharmacological strategies, non-pharmacological approaches, and complementary and alternative medicine) to control selected side-effects associated with adjuvant endocrine therapy (hot flashes, sexual dysfunction, weight gain, musculoskeletal symptoms, and fatigue), providing updated, evidence-based approaches for their management.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests LDM reports an advisory role for Roche, Novartis, Merck Sharp and Dohme, Pfizer, Ipsen, AstraZeneca, Genomic Health, Lilly, Seattle Genetics, Eisai, Pierre Fabre, and Daiichi Sankyo; honoraria from Roche, Novartis, Lilly, and Merck Sharp and Dohme; and travel grants from Roche, Pfizer, and Celgene. IV-L reports honoraria paid to institution from AstraZeneca, Amgen, and Pfizer. EdA reports honoraria from and an advisory board for Roche; and travel grants from Roche, and Novartis; research grants from Roche, Radius, AstraZeneca, Lilly, Merck Sharp and Dohme, Novartis, Synthon, Servier, and Pfizer paid to Institut Jules Bordet. AHP reports royalty payments for coauthoring the breast cancer survivorship section of UpToDate. ML reports an advisory role for Roche, Lilly, AstraZeneca, and Novartis; and honoraria from Pfizer, Lilly, Takeda, Novartis, Roche, and Sandoz. All other authors declare no competing interests.

Publication types

MeSH terms

Substances

LinkOut - more resources